We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Cytovale

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-movin... read more Featured Products: More products

Download Mobile App





New Study Reveals Rapid Sepsis Test Drives 56% Boost in ED Discharges

By LabMedica International staff writers
Posted on 31 Jul 2025

Every year, emergency departments (EDs) in the United States record over 155 million visits, with around 20% of adults showing signs of potentially serious infections. More...

One of the most critical choices emergency clinicians must make is determining which of these patients has sepsis and which do not. In situations where time is of the essence, the ability to swiftly and accurately rule out sepsis can significantly influence patient outcomes, the quality of care, hospital finances, and the overall efficiency of the healthcare system.

At the same time, overcrowding in EDs continues to put pressure on hospital operations and affect patient satisfaction. Over a 12-month span, average ED boarding times rose from 167 to 175 minutes, while the percentage of patients leaving without being seen increased from 1.1% to 2.1%, raising serious safety concerns. In such a context, being overly cautious and admitting patients out of concern for sepsis—though done with good intentions—can worsen crowding and slow down treatment for others, including those who are actually septic. Now, new multicenter study data presented at ADLM 2025 reveal that targeted sepsis testing at triage in the ED may be key to preserving inpatient bed capacity for the most severe patients.

Cytovale’s (San Francisco, CA, USA) IntelliSep is a rapid diagnostic tool for sepsis that supports emergency clinicians in making more confident decisions by quickly assessing patients’ sepsis risk. This U.S. Food and Drug Administration-cleared diagnostic, which provides results in roughly eight minutes from a standard blood draw, can be used at the triage stage to stratify patients based on their risk. The quick results help clinicians distinguish those who can be safely discharged from those needing urgent care and possible hospitalization. The study shared at ADLM 2025 involved 4,650 patients showing signs and symptoms of infection, who were tested with IntelliSep over a four-month period at four hospitals.

Using IntelliSep's rapid host-response test led to a 56% relative increase in discharges from the ED among patients identified as low risk, while simultaneously reducing the use of inpatient beds—without causing a rise in return visits. By applying this risk assessment tool early during triage, clinicians were able to avoid unnecessary admissions and discharge patients more confidently. The findings emphasize that smarter, data-driven sepsis evaluations at triage can have a direct effect on hospital capacity by boosting the number of safe discharge decisions.

Related Links:
Cytovale


New
Gold Member
Hematology Analyzer
Medonic M32B
Portable Electronic Pipette
Mini 96
New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
New
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The study highlights the potential of cCAFs as a biomarker for early diagnosis and prognosis (H J Woo et al., Analytical Chemistry (2025). DOI: 10.1021/acs.analchem.5c02154)

Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy

Accurate cancer diagnosis remains a challenge, as liquid biopsy techniques often fail to capture the complexity of tumor biology. Traditional systems for isolating circulating tumor cells (CTCs) vary in... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.